Relationship between asprosin and certain biochemical parameters in obese patients

N. S. Humadi; N. A. Saleh

doi:10.15421/0225059

N. S. Humadi Aliraqia University
N. A. Saleh Tikrit Unversity

Keywords: asprosin, obesity, leptin, adiponectin, zinc, metabolic disorders.

Abstract

Obesity is a widespread health issue among children and adolescents, driven by genetic and environmental factors. It results from low energy expenditure and excessive caloric intake, leading to complications like hypertension, metabolic disorders, card i ovascular disease, diabetes, and arthritis. The current study aimed to estimate the levels of asprosin, leptin, adiponectin, and zinc in obese individuals and to analyze their correlation with obesity-related metabolic disorders. The study collected 60 blood sa m ples from obese individuals (30 males, 30 females) and 60 from healthy controls in Baghdad, Iraq. Asprosin, leptin, and adip o nectin levels were measured using ELISA, involving antibody reactions and spectrophotometric detection at 450 nm. Zinc co n centration was determined through its reaction with 5-Br-PADAP, forming a color complex measured at 560 nm. The findings revealed an increase in asprosin levels in obese individuals, supporting its role as a potential biomarker for obesity and metabolic disorders. Additionally, leptin levels were elevated in obese subjects, while adiponectin and zinc levels were significantly lower in comparison to healthy controls. This study highlights the potential role of asprosin as a biomarker and therapeutic target for obesity. The observed alterations in leptin, adiponectin, and zinc levels further emphasize the metabolic dysregulation associated with obesity.

References

Ahmed, B., Sultana, R., & Greene, M. W. (2021). Adipose tissue and insulin resistance in obese. Biomedicine and Pharmacotherapy, 137, 111315.

Andleeb, J., Javaid, S., & Karim, R. A. (2020). Correlation of leptin level with obesity. The Professional Medical Journal, 27(6), 1139–1142.

Baltaci, A., & Mogulkoc, R. (2012). Leptin and zinc relation: In regulation of food intake and immunity. Indian Journal of Endocrinology and Metabolism, 16(9), 611–616.

Barter, P. J. (2013). High density lipoprotein: A therapeutic target in type 2 diabetes. Endocrinology and Metabolism, 28(3), 169–177.

Beutler, L. R., & Knight, Z. A. (2018). A spotlight on appetite. Neuron, 97(4), 739–741.

Ceperuelo-Mallafré, V., Näf, S., Escoté, X., Caubet, E., Gomez, J. M., Miranda, M., Chacon, M. R., Gonzalez-Clemente, J. M., Gallart, L., Gutierrez, C., & Vendrell, J. (2009). Circulating and adipose tissue gene expression of zinc-α2-glycoprotein in obesity: Its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. The Journal of Clinical Endocrinology and Metabolism, 94(12), 5062–5069.

Clemente-Suárez, V. J., Redondo-Flórez, L., Beltrán-Velasco, A. I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2023). The role of adipokines in health and disease. Biomedicines, 11(5), 1290.

Coelho, M., Oliveira, T., & Fernandes, R. (2013). State of the art paper biochemistry of adipose tissue: An endocrine organ. Archives of Medical Science, 2, 191–200.

Ennes Dourado Ferro, F., de Sousa Lima, V. B., Mello Soares, N. R., Franciscato Cozzolino, S. M., & do Nascimento Marreiro, D. (2011). Biomarkers of metabolic syndrome and its relationship with the zinc nutritional status in obese women. Nutricion Hospitalaria, 26(3), 650–654.

Feitosa, M. C. P., Lima, V. B. de S., Neto, J. M. M., & Marreiro, D. do N. (2013). Plasma concentration of IL-6 and TNF-α and its relationship with zincemia in obese women. Revista Da Associação Médica Brasileira, 59(5), 429–434.

Feng, B., Xu, P., & He, Y. (2020). Novel targets in glucose homeostasis and obesity – lesson from rare mutations. Current Diabetes Reports, 20, 66.

Ferris, W. F., Naran, N. H., Crowther, N. J., Rheeder, P., van der Merwe, L., & Chetty, N. (2005). The relationship between insulin sensitivity and serum adiponectin levels in three population groups. Hormone and Metabolic Research, 37(11), 695–701.

Franco, C., & Canzoniero, L. M. T. (2024). Zinc homeostasis and redox alterations in obesity. Frontiers in Endocrinology, 14, 1273177.

García, O. P., Ronquillo, D., Caamaño, M. del C., Camacho, M., Long, K. Z., & Rosado, J. L. (2012). Zinc, vitamin A, and vitamin C status are associated with leptin concentrations and obesity in Mexican women: Results from a cross-sectional study. Nutrition and Metabolism, 9(1), 59.

Gariballa, S., Alkaabi, J., Yasin, J., & Al Essa, A. (2017). Oxidative damage and associated inflammatory risk factors in obese Emirati women. Saudi Medical Journal, 38(9), 960–964.

Gariballa, S., Kosanovic, M., Yasin, J., & Essa, A. (2014). Oxidative damage and inflammation in obese diabetic Emirati subjects. Nutrients, 6(11), 4872–4880.

Guerre-Millo, M. (2004). Adipose tissue and adipokines: For better or worse. Diabetes and Metabolism, 30(1), 13–19.

Hernández-Camacho, J. D., Vicente-García, C., Parsons, D. S., & Navas-Enamorado, I. (2020). Zinc at the crossroads of exercise and proteostasis. Redox Biology, 35, 101529.

Konukoglu, D., Turhan, M. S., Ercan, M., & Serin, O. (2004). Relationship between plasma leptin and zinc levels and the effect of insulin and oxidative stress on leptin levels in obese diabetic patients. The Journal of Nutritional Biochemistry, 15(12), 757–760.

Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023). Insulin resistance and cardiovascular disease. Journal of International Medical Research, 51(3), 1–49.

Liu, C., Feng, X., Li, Q., Wang, Y., Li, Q., & Hua, M. (2016). Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine, 86, 100–109.

Loos, R. J. F., & Yeo, G. S. H. (2021). The genetics of obesity: From discovery to biology. Nature Reviews Genetics, 23(2), 120–133.

Luo, L., & Liu, M. (2022). Adiponectin: friend or foe in obesity and inflammation. Medical Review, 2(4), 349–362.

Ma, H., Zhang, G., Mou, C., Fu, X., & Chen, Y. (2018). Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice. Frontiers in Pharmacology, 9, 156.

Mracek, T., Ding, Q., Tzanavari, T., Kos, K., Pinkney, J., Wilding, J., Trayhurn, P., & Bing, C. (2010). The adipokine zinc-α2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. Clinical Endocrinology, 72(3), 334–341.

Nguyen, T. D. (2020). Adiponectin: Role in physiology and pathophysiology. International Journal of Preventive Medicine, 11(1), 136.

Nigro, E., Scudiero, O., Monaco, M. L., Palmieri, A., Mazzarella, G., Costagliola, C., Bianco, A., & Daniele, A. (2014). New insight into adiponectin role in obesity and obesity-related diseases. BioMed Research International, 2014, 658913.

Oussaada, S. M., van Galen, K. A., Cooiman, M. I., Kleinendorst, L., Hazebroek, E. J., van Haelst, M. M., ter Horst, K. W., & Serlie, M. J. (2019). The pathogenesis of obesity. Metabolism, 92, 26–36.

Ovali, M. A., & Bozgeyik, I. (2022). Asprosin, a C-terminal cleavage product of fibrillin 1 encoded by the FBN1 gene, in health and disease. Molecular Syndromology, 13(3), 175–183.

Peelman, F., Waelput, W., Iserentant, H., Lavens, D., Eyckerman, S., Zabeau, L., & Tavernier, J. (2004). Leptin: Linking adipocyte metabolism with cardiovascular and autoimmune diseases. Progress in Lipid Research, 43(4), 283–301.

Pérez-Torres, I., Castrejón-Téllez, V., Soto, M. E., Rubio-Ruiz, M. E., Manzano-Pech, L., & Guarner-Lans, V. (2021). Oxidative stress, plant natural antioxidants, and obesity. International Journal of Molecular Sciences, 22(4), 1786.

Picó, C., Palou, M., Pomar, C. A., Rodríguez, A. M., & Palou, A. (2021). Leptin as a key regulator of the adipose organ. Reviews in Endocrine and Metabolic Disorders, 23(1), 13–30.

Prakash, J., Mittal, B., Awasthi, S., Agarwal, C. G., & Srivastava, N. (2012). Hypoadiponectinemia in obesity: Association with insulin resistance. Indian Journal of Clinical Biochemistry, 28(2), 158–163.

Ramakrishnan, N., Auger, K., Rahimi, N., & Jialal, I. (2023). Biochemistry, adiponectin. StatPearls Publishing, Treasure Island.

Sagar, R., & Gupta, T. (2017). Psychological aspects of obesity in children and adolescents. The Indian Journal of Pediatrics, 85(7), 554–559.

Senyigit, A., Durmus, S., Tabak, O., Oruc, A., Uzun, H., & Ekinci, I. (2024). The associations between asprosine, clusterin, zinc alpha-2-glycoprotein, nuclear factor kappa B, and peroxisome proliferator-activated receptor gamma in the development of complications in type 2 diabetes mellitus. Journal of Clinical Medicine, 13(20), 6126.

Shabir, K., Brown, J. E., Afzal, I., Gharanei, S., Weickert, M. O., Barber, T. M., Kyrou, I., & Randeva, H. S. (2021). Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence. Cytokine and Growth Factor Reviews, 60, 120–132.

Shah, A., Hernandez, A., Mathur, D., Budoff, M. J., & Kanaya, A. M. (2011). Adipokines and body fat composition in South Asians: Results of the metabolic syndrome and atherosclerosis in South Asians living in America (MASALA) study. International Journal of Obesity, 36(6), 810–816.

Smith, J., Al-Amri, M., Sniderman, A., & Cianflone, K. (2006). Leptin and adiponectin in relation to body fat percentage, waist to hip ratio and the apoB/apoA1 ratio in Asian Indian and Caucasian men and women. Nutrition and Metabolism, 3(1), 18.

Tabatabaie, M., Soltani, S., Mozaffari-Khosravi, H., & Salehi-Abargouei, A. (2021). Zinc supplementation might not affect serum leptin and adiponectin levels in adults: A systematic review and meta-analysis of randomized controlled clinical trials. Iranian Journal of Public Health, 50(2), 5337.

Ugur, K., & Aydin, S. (2019). Saliva and blood asprosin hormone concentration associated with obesity. International Journal of Endocrinology, 2019, 2521096.

Wang, M., Yin, C., Wang, L., Liu, Y., Li, H., Li, M., Yi, X., & Xiao, Y. (2019). Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Annals of Nutrition and Metabolism, 75(4), 205–212.

Wang, Y., Qu, H., Xiong, X., Qiu, Y., Liao, Y., Chen, Y., Zheng, Y., & Zheng, H. (2018). Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of Inflammation, 2018, 9471583.

Wang, Z. V., & Scherer, P. E. (2016). Adiponectin, the past two decades. Journal of Molecular Cell Biology, 8(2), 93–100.

Woodward, L., Akoumianakis, I., & Antoniades, C. (2016). Unravelling the adiponectin paradox: Novel roles of adiponectin in the regulation of cardiovascular disease. British Journal of Pharmacology, 174(22), 4007–4020.

Zhang, L., Chen, C., Zhou, N., Fu, Y., & Cheng, X. (2019). Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica Chimica Acta, 489, 183–188.

Zhang, Y., Yang, P., Zhang, X., Liu, S., & Lou, K. (2024). Asprosin: Its function as a novel endocrine factor in metabolic-related diseases. Journal of Endocrinological Investigation, 47(8), 1839–1850.